CME

Faculty: Prof. Dr. Johann Bauersachs Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and...

Faculty: Prof. Dr. Johann Bauersachs Faculty: Javed Butler, MD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization,...

Faculty: Prof. Dr. Johann Bauersachs Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and...

Faculty: Javed Butler, MD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple...

Faculty: Javed Butler, MD Faculty: April W. Armstrong, MD, MPH Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization,...

Faculty: Taofeek K. Owonikoko, MD, PhD This online educational activity reviews the scientific rationale for B7-H3 as a therapeutic target in extensive-stage small cell lung cancer (ES-SCLC). Tune in for recent clinical trial data on B7-H3–directed antibody-drug conjugates in ES-SCLC, including key efficacy and safety outcomes in pretreated populations. Learners will gain practical guidance on...

Faculty: Prof. Dr. Johann Bauersachs Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Contemporary trial data and global registries consistently show that ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event still carry residual risk of cardiovascular death and heart failure hospitalizations. These annual...

Faculty: María-Victoria Mateos, MD, PhD Faculty: Luciano Costa, M.D., Ph.D. This educational activity examines the growing evidence supporting bispecific antibodies in earlier treatment lines of multiple myeloma. Experts discuss the rationale for upstream use of bispecific antibodies and review key data from pivotal trials highlighting the evolving role for bispecific antibodies as early-line...

Faculty: David Eichenbaum, MD In this didactic case presentation, Dr. David Eichenbaum discusses an 88-year-old patient with non-central geographic atrophy who received inappropriate bevacizumab treatment due to uncoordinated care after relocating seasonally. The case illustrates challenges that can arise in managing retinal disease across geographically distant sites. Dr. Eichenbaum emphasizes...

Faculty: William Wierda, MD, PhD Faculty: Matthew S. Davids, MD, MMSc This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetoclax-based regimens, while highlighting considerations such as comorbidities,...